Get the Stockscreener App
51.75
1.02%
0.52
After Hours:
51.75
Merus N V stock is traded at $51.75, with a volume of 244.52K.
It is up +1.02% in the last 24 hours and down -0.06% over the past month.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
See More
Previous Close:
$51.23
Open:
$48.91
24h Volume:
244.52K
Relative Volume:
0.52
Market Cap:
$3.54B
Revenue:
$38.34M
Net Income/Loss:
$-149.65M
P/E Ratio:
-13.76
EPS:
-3.76
Net Cash Flow:
$-150.28M
1W Performance:
-0.33%
1M Performance:
-0.06%
6M Performance:
+7.01%
1Y Performance:
+108.00%
1-Day Range:
$48.42
$51.95
1-Week Range:
$48.42
$52.39
52-Week Range:
$22.01
$61.61
Merus N V Stock (MRUS) Company Profile
Name
Merus N V
Sector
Industry
Phone
31 030 253 8800
Address
YALELAAN 62, 3584 CM UTRECHT
Merus N V Stock (MRUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-02-23 | Initiated | Canaccord Genuity | Buy |
| Aug-21-23 | Initiated | TD Cowen | Outperform |
| Aug-02-22 | Initiated | Stifel | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Needham | Buy |
| Nov-17-21 | Resumed | Guggenheim | Buy |
| Jun-07-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-08-21 | Initiated | William Blair | Outperform |
| Mar-16-21 | Initiated | SVB Leerink | Outperform |
| Jun-26-20 | Initiated | H.C. Wainwright | Buy |
| May-27-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-20-19 | Resumed | Guggenheim | Buy |
| Jun-28-19 | Initiated | ROTH Capital | Buy |
| Apr-12-19 | Resumed | Guggenheim | Buy |
| Apr-03-19 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Jan-02-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Mar-21-17 | Downgrade | Citigroup | Buy → Neutral |
| Dec-22-16 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-16 | Downgrade | Citigroup | Buy → Neutral |
| Jun-13-16 | Initiated | Citigroup | Buy |
| Jun-13-16 | Initiated | Guggenheim | Buy |
| Jun-13-16 | Initiated | Wedbush | Outperform |
View All
Merus N V Stock (MRUS) Latest News
FDA extends review date for Merus' cancer drug Zeno By Investing.com - Investing.com UK
Merus (NASDAQ:MRUS) Shares Gap DownHere's Why - MarketBeat
Merus: Petosemtamab Set Up For December 2024 Data Presentation (NASDAQ:MRUS) - Seeking Alpha
US FDA extends review of Merus' gene-targeting cancer therapy - Reuters
US FDA extends review of Merus’ gene-targeting cancer therapy - PharmaLive
Merus stock slips as FDA delays drug review (MRUS:NASDAQ) - Seeking Alpha
FDA extends review period for Merus's cancer drug Zeno - Investing.com
Merus Receives FDA extension of PDUFA for zenocutuzumab - GlobeNewswire
Harbor Capital Advisors Inc. Makes New Investment in Merus (NASDAQ:MRUS) - MarketBeat
abrdn plc Acquires Shares of 87,215 Merus (NASDAQ:MRUS) - MarketBeat
Merus sees cash runway into 2028 - MSN
Merus reports Q3 EPS ($1.46), consensus (88c) - MSN
Merus annonce ses résultats financiers pour le troisième trimestre 2024 et fait le point sur ses activités - GlobeNewswire Inc.
Merus (NASDAQ:MRUS) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Merus N.V. Reports Q3 2024 Financial Results - TipRanks
Merus falls after updated data for lung cancer therapy - MSN
Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update - GlobeNewswire
Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Novo Holdings A S Increases Position in Merus (NASDAQ:MRUS) - MarketBeat
Merus (NASDAQ:MRUS) Coverage Initiated at UBS Group - Defense World
UBS sees upside in Merus stock, highlights potential in head and neck cancer treatment - Investing.com India
Moody Aldrich Partners LLC Makes New Investment in Merus (NASDAQ:MRUS) - MarketBeat
UBS sees upside in Merus stock, highlights potential in head and neck cancer treatment By Investing.com - Investing.com South Africa
Merus (NASDAQ:MRUS) Receives New Coverage from Analysts at UBS Group - MarketBeat
(MRUS) Investment Report - Stock Traders Daily
nVerses Capital LLC Acquires 1,500 Shares of Merus (NASDAQ:MRUS) - Defense World
Investing in Merus (NASDAQ:MRUS) five years ago would have delivered you a 227% gain - Yahoo Finance
Analysts Set Merus (NASDAQ:MRUS) Target Price at $82.00 - Defense World
Market Resilience: Merus N.V (MRUS) Finishes Weak at 51.35, Down -1.57 - The Dwinnex
Data Readouts At ASCO (MRUS, ORIC, CGEN, PDSB...) - RTTNews
A company insider recently sold 2,500 shares of Merus N.V [MRUS]. Should You also Consider to Sale? - Knox Daily
A History of Outperforming Analyst Forecasts and Beating the Odds: Merus N.V (MRUS) - SETE News
Merus (NASDAQ:MRUS) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
VP Controller, PAO Shuman Harry sale 2,500 shares of Merus N.V [MRUS] - Knox Daily
Market Highlights: Merus N.V (MRUS) Ends on a Low Note at 52.09 - The Dwinnex
There is no way Merus N.V (MRUS) can keep these numbers up - SETE News
What is the investor’s view on Merus N.V (MRUS)? - US Post News
Merus N.V (MRUS) receives a Buy rating from Truist - Knox Daily
Merus (NASDAQ:MRUS) Holdings Lowered by The Manufacturers Life Insurance Company - Defense World
Millennium Management LLC Has $14.39 Million Stock Position in Merus (NASDAQ:MRUS) - MarketBeat
Prepare Yourself for Liftoff: Merus N.V (MRUS) - SETE News
Guggenheim Raises Merus (NASDAQ:MRUS) Price Target to $111.00 - MarketBeat
Checking in on Merus N.V (MRUS) after recent insiders movement - Knox Daily
Merus (NASDAQ:MRUS) Price Target Raised to $111.00 at Guggenheim - Defense World
Merus NV: Driving Innovation in Cancer Treatment with Shares Valued at $50.33 - NasdaqNewsFeed
Merus begins phase 3 trial for head and neck cancer therapy - Investing.com Canada
Merus (NASDAQ:MRUS) Shares Up 4.7% - Defense World
Merus's SWOT analysis: bispecific antibody developer's stock shows promise - Investing.com India
BMO maintains Merus $95 target on positive trial data By Investing.com - Investing.com Canada
Merus begins phase 3 trial for head and neck cancer therapy By Investing.com - Investing.com South Africa
Merus's SWOT analysis: bispecific antibody developer's stock shows promise By Investing.com - Investing.com Australia
Merus N V Stock (MRUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Merus N V Stock (MRUS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shuman Harry | VP Controller, PAO |
Aug 20 '24 |
Sale |
54.00 |
2,500 |
135,000 |
7,002 |
| Silverman Peter B. | COO & GC |
Jun 27 '24 |
Option Exercise |
17.94 |
10,000 |
179,400 |
10,000 |
| Silverman Peter B. | COO & GC |
Jun 27 '24 |
Sale |
60.00 |
10,000 |
600,000 |
0 |
| Silverman Peter B. | COO & GC |
Jun 17 '24 |
Option Exercise |
24.36 |
62,000 |
1,510,280 |
62,000 |
| Silverman Peter B. | COO & GC |
Jun 17 '24 |
Sale |
56.52 |
62,000 |
3,504,178 |
0 |
| Shuman Harry | VP Controller, PAO |
Jun 12 '24 |
Sale |
57.84 |
7,300 |
422,232 |
7,002 |
| Shuman Harry | VP Controller, PAO |
Jun 10 '24 |
Sale |
53.22 |
1,000 |
53,224 |
7,002 |
| Shuman Harry | VP Controller, PAO |
Jun 04 '24 |
Sale |
52.89 |
6,000 |
317,354 |
7,002 |
| Shuman Harry | VP Controller, PAO |
Dec 19 '23 |
Sale |
26.68 |
115 |
3,068 |
7,002 |
| Silverman Peter B. | COO & GC |
Dec 15 '23 |
Sale |
25.00 |
22,386 |
559,650 |
0 |
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):